Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
13739-02-1
Molecular formula
C19H12O8
Molecular weight
368.29 g/mol
Drug class
Anthraquinone derivativesymptomatic slow-acting medicine for osteoarthritis (SYSADOA)
Mechanism of action
Inhibits interleukin-1 beta activity and related inflammatory/catabolic pathways involved in cartilage degradation. It is a slow-acting agent and its clinical benefit may take several weeks to appear.
Indications / reported uses
Symptomatic treatment of osteoarthritis of the hip or knee only, where authorised; not recommended for rapidly progressive hip OA. EMA restrictions: do not use in patients aged 65 years or older or in those with current or previous liver disease; stop treatment if diarrhoea occurs and monitor for hepatic injury.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Diacerein PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Diacerein Permitted Daily Exposure (PDE) report (the Diacerein PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Diacerein Occupational Exposure Limit (OEL) report (the Diacerein OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.